International conferences and seminars
Diabetes Summit 2013
Dr. Riccardo Perfetti, Vice President of Global Medical Affairs in the Diabetes Division at Sanofi, will give the keynote presentation, "The Most Recent ADA/EASD Guidelines are Changing the Development Strategies: A Focus Combination Therapy for the Treatment of Diabetes" at the Diabetes Summit 2013. In his current role, Dr. Perfetti is engaged in defining the interaction between the Diabetes Division and the outside interlocutors including academia, key opinion leaders, regulatory bodies, and the payers.
Come and network with experts in the diabetes field and hear key thought-leaders discuss research in drug development and partnering strategies to bring new therapeutics to market. This important meeting will be held on April 29-30, 2013 in Boston, MA. Join colleagues from both industry and academia to discuss novel targets for diabetes and lessons learned from the latest research.
The Diabetes Summit 2013 consists of two concurrent tracks:
3rd Diabetes Partnering and Deal-Making
6th Diabetes Drug Discovery and Development
Register before February 28th and save up to $375!
Bring your team!
Register 3 people for the price of 2! Use discount code rcdvb.
DISTINGUISHED SPEAKERS & PANELISTS
Riccardo Perfetti, Vice President, Global Medical Affairs, Sanofi - KEYNOTE
Allan Ertmann Karlsen, Corporate Vice President, Diabetes Biology, Novo Nordisk A/S - FEATURED
Steven Burrill, CEO, Burrill & Company - FEATURED
Ed Damiano, Associate Professor, Biomedical Engineering, Boston University - FEATURED
Mostafa Analoui, Head; Healthcare and Life Sciences, The Livingston Group
William Bachovchin, Professor, Biochemistry, Tufts University
Natalia Borinshteyn, Head, Portfolio Strategy Novel Prevention & Cure approaches, Global Diabetes Division, Sanofi-aventis
John Brooks, President and Chief Executive Officer, Joslin Diabetes Center, Harvard Medical School
Richard Caroddo, Business Development Executive, Medpace
Barbara Corkey, Vice Chair for Research, Boston University School of Medicine
Hakan.S.Edstrom, President and Chief Operating Officer, MannKind Corporation
Brad Fell, Senior Research Investigator; Medicinal Chemistry, Array BioPharma
Mason Freeman, Chief of Lipid Metabolism Unit, Massachusetts General Hospital, Harvard Medical School
Dan Grau, President, Heptares Therapeutics
Kurt Graves, Executive Chairman & CEO, Intarcia Therapeutics
Bart Henderson, President & Founder, Rhythm
Urban Kiernan, Senior Scientist, Thermo Fisher Scientific
Dennis Kim, Chief Medical Officer, Zafgen
Thomas Kuhn, CEO, Poxel
George Kunos, Scientific Director, NIAAA/NIH
Tomas Landh, Director, Stragegy and Sourcing, Diabetes Research Unit, Novo-Nordisk
Randall Nelson, Research Professor, Molecular Biomarkers Lab, Arizona State University
Christoph Pittius, Vice President, Partnering & Business Development, Astrazeneca
Dietrich Rein, Manager Biomarker Development, Metanomics Health GmbH
Karen Segal, Senior Vice President, Diabetes and Metabolic Diseases, Meso Blast
Lauren Shearman, Strategic Licensing & Acquisitions Lead, Diabetes & Endocrinology, External Scientific Affairs, Worldwide Licensing & Acquisitions, Merck
Peter Stein, Head; Development Metabolism, Janssen R&D US
Solomon Steiner, Managing Director, Steiner Ventures
Becky Taub, CEO, Madrigal Pharmaceuticals
Vince Wacher, CEO, Verva
Jim Wang, VP, Cardiovascular and Metabolic Diseases Research, Crown Bioscience (Taicang) Inc.
Gordon Weir, Islet Transplantation and Cell Biology, Joslin Diabetes Center, Harvard Medical School
For the latest list of speakers, please go to www.gtcbio.com/diabetes/speakers